Karyopharm Therapeutics (NASDAQ:KPTI) Downgraded by Robert W. Baird to Neutral

Robert W. Baird cut shares of Karyopharm Therapeutics (NASDAQ:KPTI) from an outperform rating to a neutral rating in a research report released on Friday morning, Marketbeat.com reports. They currently have $3.00 target price on the stock.

KPTI has been the topic of several other research reports. HC Wainwright downgraded shares of Karyopharm Therapeutics from a “buy” rating to a “negative” rating in a report on Friday. Royal Bank Of Canada restated an “outperform” rating and set a $16.00 price objective on shares of Karyopharm Therapeutics in a research note on Tuesday, July 21st. Weiss Ratings downgraded shares of Karyopharm Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday. Piper Sandler reiterated an “overweight” rating and issued a $16.00 price objective (up from $8.00) on shares of Karyopharm Therapeutics in a research note on Monday, April 27th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Karyopharm Therapeutics in a report on Tuesday, June 9th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $11.50.

Karyopharm Therapeutics Stock Performance

Shares of KPTI opened at $1.92 on Friday. The stock has a 50-day moving average of $8.88 and a two-hundred day moving average of $8.19. Karyopharm Therapeutics has a one year low of $1.80 and a one year high of $10.99. The stock has a market cap of $43.51 million, a P/E ratio of -0.13 and a beta of 0.80.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($1.24) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.45) by $0.21. The firm had revenue of $35.07 million during the quarter, compared to analyst estimates of $31.40 million. Analysts predict that Karyopharm Therapeutics will post -3.24 EPS for the current fiscal year.

Institutional Trading of Karyopharm Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the company. Commodore Capital LP acquired a new stake in shares of Karyopharm Therapeutics during the 1st quarter valued at about $10,862,000. T. Rowe Price Investment Management Inc. raised its stake in Karyopharm Therapeutics by 112.8% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,491,409 shares of the company’s stock valued at $10,977,000 after purchasing an additional 790,417 shares during the last quarter. Ikarian Capital LLC raised its position in shares of Karyopharm Therapeutics by 1,897.9% in the fourth quarter. Ikarian Capital LLC now owns 544,554 shares of the company’s stock valued at $4,008,000 after buying an additional 517,297 shares during the last quarter. Avidity Partners Management LP grew its stake in Karyopharm Therapeutics by 244.6% during the 1st quarter. Avidity Partners Management LP now owns 463,741 shares of the company’s stock valued at $2,583,000 after acquiring an additional 329,175 shares in the last quarter. Finally, Boothbay Fund Management LLC purchased a new stake in Karyopharm Therapeutics during the 4th quarter valued at about $1,064,000. 66.44% of the stock is owned by hedge funds and other institutional investors.

Karyopharm Therapeutics News Summary

Here are the key news stories impacting Karyopharm Therapeutics this week:

• Positive Sentiment: Karyopharm plans to submit a supplemental New Drug Application in August 2026 seeking accelerated FDA approval for selinexor combined with ruxolitinib in myelofibrosis. The company will request priority review, and approval could make the treatment the first approved combination therapy in this setting. Karyopharm myelofibrosis sNDA announcement
• Positive Sentiment: Piper Sandler maintained an “overweight” rating while lowering its price target to $7.00. The target still indicates substantial potential upside if Karyopharm’s pipeline programs succeed.
• Neutral Sentiment: HC Wainwright reaffirmed its “neutral” rating but cut its price target to $3.00 from $13.00, reflecting sharply reduced expectations after the endometrial-cancer update.
• Neutral Sentiment: Robert W. Baird downgraded KPTI from “outperform” to “neutral” and set a $3.00 price target, signaling a more cautious view despite implied upside from recent trading levels.
• Neutral Sentiment: An executive vice president sold 189 shares for approximately $1,342, reducing the executive’s position by only 0.20%; the small transaction is unlikely to materially change the investment outlook. SEC insider transaction filing
• Negative Sentiment: Karyopharm’s Phase 3 XPORT-EC-042 trial failed to meet its primary progression-free-survival endpoint in endometrial cancer. Although median PFS favored selinexor by 5.3 months in the modified intent-to-treat population, the miss led the company to reduce investment in the program and refocus resources on myelofibrosis and multiple myeloma. Karyopharm XPORT-EC-042 trial results
• Negative Sentiment: Pomerantz LLP announced an investigation into potential claims on behalf of Karyopharm investors, adding legal overhang following the sharp decline. Pomerantz investor investigation

About Karyopharm Therapeutics

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.